COST-UTILITY ANALYSIS OF FIRST-LINE GEFITINIB, ERLOTINIB AND AFATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS

被引：0

作者：

Holleman, M. S. ^{[1
]}

Zaim, R. ^{[1
]}

Uyl-De Groot, C. A. ^{[1
]}

机构：

[1] Erasmus Univ, Inst Med Technol Assessment iMTA, Rotterdam, Netherlands

来源：

VALUE IN HEALTH | 2016年 / 19卷 / 07期

关键词：

D O I：

10.1016/j.jval.2016.09.2253

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN180

引用

页码：A740 / A741

页数：2

共 50 条

[1] COST-UTILITY ANALYSIS OF GEFITINIB AND EGFR MUTATION TESTING AS THE FIRST-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER IN VIETNAM
Tran, T. T.
[J]. VALUE IN HEALTH, 2017, 20 (05) : A112 - A112
[2] Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
Wang, Hao
Zeng, Chenxin
Li, Xin
Wang, Youjie
Li, Xinyi
Ge, Weihong
[J]. FUTURE ONCOLOGY, 2019, 15 (02) : 181 - 191
[3] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Grunberg, Steven M.
Spira, Alexander
Jaenne, Pasi A.
Joshi, Victoria A.
McCollum, David
Evans, Tracey L.
Muzikansky, Alona
Kuhlmann, Georgiana L.
Han, Moon
Goldberg, Jonathan S.
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2442 - 2449
[4] First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
Tomohito Kuwako
Hisao Imai
Tomomi Masuda
Yosuke Miura
Kaori Seki
Reiko Yoshino
Kyoichi Kaira
Mitsuyoshi Utsugi
Kimihiro Shimizu
Noriaki Sunaga
Yoshio Tomizawa
Shinichi Ishihara
Takao Ishizuka
Akira Mogi
Takeshi Hisada
Koichi Minato
Atsushi Takise
Ryusei Saito
Masanobu Yamada
[J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 761 - 769
[5] First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
Kuwako, Tomohito
Imai, Hisao
Masuda, Tomomi
Miura, Yosuke
Seki, Kaori
Yoshino, Reiko
Kaira, Kyoichi
Utsugi, Mitsuyoshi
Shimizu, Kimihiro
Sunaga, Noriaki
Tomizawa, Yoshio
Ishihara, Shinichi
Ishizuka, Takao
Mogi, Akira
Hisada, Takeshi
Minato, Koichi
Takise, Atsushi
Saito, Ryusei
Yamada, Masanobu
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 761 - 769
[6] Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Liang, Wenhua
Wu, Xuan
Fang, Wenfeng
Zhao, Yuanyuan
Yang, Yunpeng
Hu, Zhihuang
Xue, Cong
Zhang, Jing
Zhang, Jianwei
Ma, Yuxiang
Zhou, Ting
Yan, Yue
Hou, Xue
Qin, Tao
Dinglin, Xiaoxiao
Tian, Ying
Huang, Peiyu
Huang, Yan
Zhao, Hongyun
Zhang, Li
[J]. PLOS ONE, 2014, 9 (02):
[7] The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Jung, Hyun Ae
Park, Sehhoon
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Sun, Jong-Mu
[J]. CANCER RESEARCH AND TREATMENT, 2023, 55 (02): : 479 - 487
[8] CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
Kang, Liping
Mai, Jianliang
Liang, Weiting
Zou, Qihua
Huang, Caiwen
Lin, Yongbin
Liang, Ying
[J]. FRONTIERS IN ONCOLOGY, 2023, 13
[9] First-line gefitinib for elderly patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: A combined analysis of NEJ studies.
Narumi, Sodai
Inoue, Akira
Morikawa, Naoto
Minegishi, Yuji
Maemondo, Makoto
Okinaga, Shoji
Kobayashi, Kunihiko
Harada, Toshiyuki
Hagiwara, Koichi
Nukiwa, Toshihiro
Gemma, Akihiko
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[10] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
Ji, Y.
Wang, X.
Lou, Z.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979

← 1 2 3 4 5 →